The use of high-dose immunoglobulin in the treatment of pyoderma gangrenosum

被引:29
|
作者
Hagman, JH
Carrozzo, AM
Campione, E
Romanelli, P
Chimenti, S
机构
[1] Miami Univ, Sch Med, Dept Dermatol & Cutaneous Surg, Miami, FL USA
[2] Univ Roma Tor Vergata, Dept Dermatol, I-00144 Rome, Italy
关键词
immunoglobulin; pyoderma gangrenosum;
D O I
10.1080/095466301750163527
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
BACKGROUND: Immunosuppressive medications such as corticosteroids and cyclosporin are the most commonly employed therapies in pyoderma gangrenosum. We describe a patient with multiple ulcers of pyoderma gangrenosum on the lower extremities in whom immunosuppressive therapy caused serious side effects and had to be discontinued but who was subsequently treated successfully with high dose intravenous immunoglobulin (IVIG), METHODS: IVIG was given intravenously at a dose of 400 mg/kg per day for 5 consecutive days. After 1 week there was an arrest in the progression of the ulcers and a marked reduction in pain. Two weeks later clinical improvement of the ulcers was observed, Subsequently, IVIG was given at a dose of 1 g/kg per day for 2 consecutive days. RESULTS: The treatment induced a dramatic clinical improvement of one ulcer and healing of the others. Side effects were minimal and well tolerated, and consisted of chills and a slight fever, which resolved with the administration of acetaminophen. CONCLUSION: We feel that IVIG call be used in patients with pyoderma gangrenosum in whom conventional therapies are ineffective or produce serious side effects.
引用
收藏
页码:19 / 22
页数:4
相关论文
共 50 条
  • [32] Use of brodalumab for the treatment of pyoderma gangrenosum: A case report
    Huang, Chang-Ming
    Tsai, Tsen-Tsai
    DERMATOLOGICA SINICA, 2021, 39 (01) : 57 - 58
  • [33] Use of anakinra in treatment-resistant pyoderma gangrenosum
    Ng, A.
    Aamer, M.
    Warburton, K. L.
    Montgomery, R.
    Laws, P.
    BRITISH JOURNAL OF DERMATOLOGY, 2018, 179 : 71 - 72
  • [34] Pyoderma gangrenosum of the breast treated with intravenous immunoglobulin
    Sinnya, Sudipta
    Hamza, Saud
    JOURNAL OF DERMATOLOGICAL CASE REPORTS, 2013, 7 (02): : 64 - 68
  • [35] The renal risks of high-dose intravenous immunoglobulin treatment
    Stahl, M
    Schifferli, JA
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 1998, 13 (09) : 2182 - 2185
  • [36] Successful treatment of dermatomyositis with high-dose intravenous immunoglobulin
    Kuwano, Y
    Ihn, H
    Yazawa, N
    Kakinuma, T
    Asahina, A
    Kikuchi, K
    Tamaki, K
    ACTA DERMATO-VENEREOLOGICA, 2006, 86 (02) : 158 - 159
  • [37] HIGH-DOSE IMMUNOGLOBULIN IN THE TREATMENT OF MYASTHENIA-GRAVIS
    ARSURA, EL
    BICK, A
    BRUNNER, NG
    NAMBA, T
    GROB, D
    CLINICAL RESEARCH, 1985, 33 (02): : A372 - A372
  • [38] PRETIBIAL MYXEDEMA AND HIGH-DOSE INTRAVENOUS IMMUNOGLOBULIN TREATMENT
    ANTONELLI, A
    NAVARRANNE, A
    PALLA, R
    ALBERTI, B
    SARACINO, A
    MESTRE, C
    ROGER, P
    AGOSTINI, S
    BASCHIERI, L
    THYROID, 1994, 4 (04) : 399 - 408
  • [39] High-dose intravenous immunoglobulin treatment of multiple sclerosis
    Durelli, L
    Isoardo, G
    NEUROLOGICAL SCIENCES, 2002, 23 (Suppl 1) : S39 - S48
  • [40] HIGH-DOSE INTRAVENOUS IMMUNOGLOBULIN TREATMENT IN GRAVES OPHTHALMOPATHY
    ANTONELLI, A
    SARACINO, A
    ALBERTI, B
    CANAPICCHI, R
    CARTEI, F
    LEPRI, A
    LADDAGA, M
    BASCHIERI, L
    ACTA ENDOCRINOLOGICA, 1992, 126 (01): : 13 - 23